Space manufacturing could become a platform for scientific discovery and biomedical advancement, according to analytics company GlobalData. 

Analysis from GlobalData suggests environments in space are increasingly accessible, with pharmaceutical and biotech companies focusing on low-Earth orbit to explore new opportunities. This includes advancing drug development, disease modelling and therapeutic design.  

Microgravity offers unique advantages by affecting biological and chemical processes in ways that cannot be replicated on Earth. In this environment, cells and tissues grow differently, revealing insights into human health and disease progression.  

The International Space Station (ISS) has previously conducted experiments demonstrating that protein crystals grown in space are more uniform and stable, enabling the creation of more effective and targeted therapies. 

“Microgravity provides a novel insight into how biology truly operates,” said Gaffar Aga, Strategic Intelligence Analyst at GlobalData.  

“Without the interference of gravity, researchers can study cellular behaviour in its purest form, uncovering new pathways for drug discovery and innovation.” 

Space-based manufacturing ‘will be key’ in future

Space-based research has previously enabled breakthroughs in 3D bio-printing, where human tissues are printed in microgravity to create structures that cannot be formed on Earth. Such developments could potentially lead to organ printing for transplantation and regenerative therapies. Studies in protein crystallisation and nanomaterial formation also offer insights into drug formulations to improve patient outcomes.

Researchers are also leveraging the rapid ageing effects seen in microgravity to accelerate biomedical research. Cells and tissues age faster in space, allowing scientists to study degenerative conditions as well as test anti-aging treatments in shorter time-periods than required on Earth.

With the ongoing collaboration between agencies such as NASA, the UK Space Agency, and private biotech firms, space is quickly becoming a promising means of developing novel therapeutics within the pharmaceutical industry.

“As commercial access expands, space is becoming a laboratory for innovation,” added George El-Helou, Strategic Intelligence Analyst at GlobalData. 

“This offers the pharmaceutical industry an opportunity to design products and treatments that were once unheard of.”

Aga and El-Helou concluded: “As populations live longer, the need for faster and more effective therapies is critical. Space-based manufacturing and research will be key to develop the next-generation healthcare solutions.” 

 

Bruno Quinney, Content Team, DDW